Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Author:
Publisher
Elsevier BV
Subject
Cancer Research
Reference154 articles.
1. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N. Engl. J. Med.,2019
2. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol.,2020
3. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial;Eggermont;J. Clin. Oncol.,2020
4. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial;Eggermont;Lancet Oncol.,2021
5. Primary, adaptive, and acquired resistance to cancer immunotherapy;Sharma;Cell,2017
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges;MedComm – Oncology;2024-08-08
2. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies;Experimental Hematology & Oncology;2024-08-06
3. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer;BMC Cancer;2024-08-02
4. HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, −10 and −11;Biomedicine & Pharmacotherapy;2024-04
5. Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective;Cancers;2023-12-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3